Salisbury, Wiltshire, United Kingdom
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
Phase
3Span
321 weeksSponsor
Merck Sharp & Dohme LLCHanyu, Saitama
Recruiting
1-1 of 1